---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-056448"
form_type: "8-K"
ticker: "TWST"
cik: "0001581280"
company_name: "Twist Bioscience Corp"
filed_at: "2022-05-05T23:59:59+00:00"
generated_at: "2026-06-25T23:41:34.730446+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Twist Bioscience Q2 revenue $48.1M (+54% YoY), orders $55.0M (+32% YoY)

## Summary
- Record revenue $48.1M, up 54% YoY from $31.2M.
- Net loss $60.7M ($1.13/share) vs $37.9M ($0.78) prior year.
- Orders $55.0M, up 32% YoY from $41.7M.
- Four-year supply agreement with Ginkgo Bioworks, $58M minimum purchases over contract term.
- Cash $604.4M; raised $269.8M net from public offering completed in the quarter.

## SEC filing metadata
- accession: 0001104659-22-056448
- form_type: 8-K
- ticker: TWST
- cik: 0001581280
- company_name: Twist Bioscience Corp
- filed_at: 2022-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1581280/000110465922056448/0001104659-22-056448-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1581280/000110465922056448/tm2214535d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-056448
- JSON: https://secwatch.observer/filing/0001104659-22-056448.json
- Plain text: https://secwatch.observer/filing/0001104659-22-056448.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.